Influence of the co-encapsulation of different excipients on the properties of polyester microparticle-based vaccine against brucellosis.
This work evaluates the influence of different pharmaceutical auxiliaries (Pluronic F68, polyvinylpyrrolidone [PVP] or Tween 20), when mixed with an antigenic extract from Brucella ovis (hot saline; HS), on the characteristics of the resulting poly(epsilon-caprolactone) (PEC) and poly(lactide-co-glycolide) (PLGA) microparticles. In all cases, PEC microparticles were smaller than PLGA ones. Concerning the HS loading, PLGA microparticles were highly dependent on the type of the excipient used, whereas all the PEC formulations displayed similar encapsulation efficiencies. For both types of microparticles, the presence of PVP induced a burst release effect. On the contrary, the use of Tween 20 or Pluronic F68 dramatically modified this profile. For PLGA-Tween 20 and PEC-Pluronic F68 microparticles, the HS was released in a pulsatil way during the first 7 days followed by a continuous release for at least 3 weeks. The antigenicity of the HS components was kept in all cases. Phagocytosis by murine monocytes showed a clear difference based just on the hydrophobicity of the polymer, being PEC microparticles better engulfed. Cell activation quantified by the release of H2O2 did not showed major differences between batches, however, microparticles of PEC and Pluronic F68 induced the highest nitric oxide production. Together, these results confirm the advantageous qualities of the "HS-PEC-Pluronic F68 microparticles" as favorable candidate for vaccine purposes against brucellosis.
Murillo
M
M
Department of Pharmaceutical Technology, University of Navarra, 31008 Pamplona, Spain.
Irache
J M
JM
Estevan
M
M
Goñi
M M
MM
Blasco
J M
JM
Gamazo
C
C
D000818:Animals; D002004:Brucella Vaccine / Q000737:chemistry* / Q000276:immunology; D042061:Brucella ovis / Q000737:chemistry / Q000276:immunology; D002006:Brucellosis / Q000517:prevention & control*; D004591:Electrophoresis, Polyacrylamide Gel; D005079:Excipients / Q000737:chemistry*; D015151:Immunoblotting; D066298:In Vitro Techniques; D019344:Lactic Acid / Q000737:chemistry*; D008262:Macrophage Activation; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D010587:Phagocytosis; D020442:Poloxamer / Q000737:chemistry; D011091:Polyesters / Q000737:chemistry*; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry*; D011136:Polysorbates / Q000737:chemistry; D011205:Povidone / Q000737:chemistry; D012995:Solubility
D002004:Brucella Vaccine; D005079:Excipients; D011091:Polyesters; D011108:Polymers; D011136:Polysorbates; D020442:Poloxamer; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; C016240:polycaprolactone; D011100:Polyglycolic Acid; D019344:Lactic Acid; D011205:Povidone